Regado Biosciences, Inc.

Regado Biosciences, Inc. is a biotechnology company focused on the development of innovative therapies aimed at improving patient outcomes in cardiovascular diseases. Regado Biosciences, Inc. specializes in developing cutting-edge therapies for cardiovascular conditions.

Founded in 2001 and headquartered in the United States, the company has undergone significant changes, including its acquisition by Tobira Therapeutics in May 2015, which led to Tobira going public. Regado has raised a total of USD 43. 00 mn through various funding rounds, with the latest being an IPO in August 2013, pricing at USD 4 per share. The company has completed 9 deals to date.

Regado Biosciences, Inc. primarily focuses on the development of innovative therapeutic agents for treating cardiovascular diseases. Their research and development efforts are centered around novel anticoagulants designed to enhance patient safety and efficacy in managing serious medical conditions associated with blood clotting. In the most recent year, 2014, Regado Biosciences, Inc.

reported zero revenue with an EBITDA of USD -66. 22 mn, reflecting the challenges faced in transitioning from research to market application of its therapeutic developments. Moving forward, Regado Biosciences intends to leverage its recent IPO funding of USD 43. 00 mn to advance the clinical development of its pipeline products.

The company is also looking to expand its market reach, particularly into Europe and Asia-Pacific, by the end of 2015, aiming to establish partnerships with healthcare providers and research institutions to enhance its product offerings.